AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
, . While the CEO projected sequential revenue growth and non-GAAP EPS improvements for 2026, .
, .
, . , , underscoring persistent financial challenges.
, .
; INSERT
HERE (same line) THEN ADD
The stock’s post-earnings performance reflects mixed investor sentiment. While daily and monthly gains suggest optimism about future milestones, the weekly decline highlights concerns over widening losses. , citing extended cash runway through 2028, .
CEO John A. Carter emphasized advancing molecular imaging agents and addressing manufacturing challenges, while expressing cautious optimism for 2026 due to late-stage trial progress and global partnerships.
The company expects sequential revenue growth in Q4 2025 and non-GAAP EPS improvements in 2026, though no specific targets were provided. Capital expenditures will focus on facility upgrades to support long-term production.
, . , . , with a Phase I update expected by year-end.
The partnership with Otsuka and recent capital raise position
to advance pivotal trials while navigating ongoing R&D costs. Analysts remain cautiously optimistic, balancing near-term losses with long-term therapeutic potential.Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet